Page 11 of 11
Are there any plans for further studies?
No studies of niraparib in combination with pembrolizumab in participants with advanced
breast cancer and ovarian cancer are ongoing or planned, and one study has been
completed.
Where can I find more information about this study?
Full title of this study: Phase 1/2 clinical study of niraparib in combination with
pembrolizumab in patients with advanced or metastatic triple-negative breast cancer and in
patients with recurrent ovarian cancer.
Clinical studies have unique study numbers. The unique study number associated with this
study is shown below with an internet link to the scientific summary.
Organisation
Study Identifier
(Website)
United States National Institutes of Health (NIH)
NCT026578891
(www.clinicaltrials.gov)
The scientific summary includes more details about the requirements for study enrolment,
the study visit schedule, results from other endpoints, and more detailed information about
adverse events.
Your doctor can help you understand more about this study and the results. You
should not make changes to your care based on the results of this or any single
study.
We would like to thank the participants who contributed to this study. The results of
this study will help answer scientific questions about treating participants with TNBC and
ovarian cancer.
The content for this document was finalised by GSK on 26 August 2022. The information in
this summary does not include additional information available after this date.
1https://clinicaltrials.gov/ct2/show/NCT02657889?term=213363